Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;35(3):222-227.
doi: 10.5455/msm.2023.35.222-227.

Current Status of Biological Treatment in Ankylosing Spondylitis Patients and Some Related Factors

Bui Hai Binh  1 , Nguyen Ngoc Trung  2 , Nguyen-Van Hung  1   3 , Nguyen-Thi Ngoc Yen  1   3 , Nguyen-Thi Nhu Hoa  4 , Nguyen Thanh Hiep  5 , Nguyen Minh Duc  6 , Le-Thi Bich Phuong  7
Affiliations

Current Status of Biological Treatment in Ankylosing Spondylitis Patients and Some Related Factors

Bui Hai Binh et al. Mater Sociomed. 2023 Sep.

Abstract

Background: Axial spondyloarthritis (axSpA) is a potentially disabling inflammatory arthritis of the spine, usually presenting as chronic back pain typically before the age of 45 years. It is often associated with one or more articular features, including synovitis, enthesitis, and dactylitis. It may also be associated with several non-articular features; these include uveitis, psoriasis, and inflammatory bowel diseases1.

Objective: The aim of this article is to describe the status of using biological drugs and some related factors in treating ankylosing spondylitis in Vietnam.

Methods: A joint prospective and retrospective cross-sectional descriptive study was conducted on 161 ankylosing spondylitis patients treated with biological drugs at the Centre for Rheumatology between January 2018 and July 2021. Data were collected at the first dose and after 3, 6, 12, 24, and 36 months, including general characteristics, clinical and para-clinical features, drug use status, and related factors.

Results: Of the 161 patients, 86.3% were male, with a mean age of 31.1 ± 11.6 years and a mean disease duration of 7.6 ± 6.6 years. Most patients were started on biologics at stage II (46.6%) or III (28.6%). Moreover, 68.9% had active disease based on the Bath Ankylosing Spondylitis Disease Activity Index. The most commonly prescribed first-line therapy was anti-tumor necrosis factor (69.6%), with infliximab the most frequently prescribed drug (44.7%). The rate of biological drug treatment decreased gradually from 100% at the start to 77% after one year and 39.1% after three years. Moreover, 74% of patients changed drugs due to non-response, and 50% discontinued treatment for economic reasons. Age was associated with treatment adherence, and drug change rates were higher in female patients and patients with active disease. Age was significantly associated with drug discontinuation (p < 0.05).

Conclusion: Infliximab was the most commonly prescribed first-line drug. The rate of biological therapy gradually decreased after three years. Most patients changed drugs due to non-response, and many discontinued the drugs for economic reasons. Among the individual and clinical factors, age was associated with treatment adherence.

Keywords: ankylosing spondylitis; bDMARD; biological drugs; treatment adherence.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1.
Figure 1.. Drug change or drug discontinuation during the study period.
See this image and copyright information in PMC

References

    1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007 Apr 21;369(9570):1379–1390. doi: 10.1016/S0140-6736(07)60635-7. - DOI - PubMed
    1. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. 2005 Apr;52(4):1000–1008. doi: 10.1002/art.20990. - DOI - PubMed
    1. Siba P. Raychaudhuri, Atul Deodhar. The classification and diagnostic criteria of ankylosing spondylitis. Journal of Autoimmunity. 2014;48-49:128–133. doi: 10.1016/j.jaut.2014.01.015. ISSN 0896-8411. - DOI - PubMed
    1. Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, Syrbe U, Braun J, Rudwaleit M. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS) Ann Rheum Dis. 2016 Aug;75(8):1438–1443. doi: 10.1136/annrheumdis-2015-207897. Epub 2015 Aug 4. - DOI - PubMed
    1. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 Oct;71(10):1599–1613. doi: 10.1002/art.41042. Epub 2019 Aug 22. - DOI - PMC - PubMed

LinkOut - more resources